Prevalence of venous obstructions in (recurrent) venous thromboembolism: a case-control study

Thrombosis Journal

Table 1 Baseline characteristics

	Recurrent VTE N = 32	No recurrent VTE N = 24	P-value
Age, years	68.0 (61.3–72.0)	65.0 (45.3–70.8)	0.223
Sex			0.298
- Male	28 (87.5)	18 (75.0)	0.298
- Female	4 (12.5)	6 (25.0)	0.298
Unprovoked DVT	23 (71.9)	10 (41.7)	0.030
Affected side initial event			0.697
- Left	13 (40.6)	11 (45.8)	0.697
- Right	19 (59.4)	13 (54.2)	0.697
Affected side recurrent event
- Ipsilateral (± pulmonary embolism)	17 (53.1)	n/a	–
- Contralateral (± pulmonary embolism)	9 (28.1)	n/a	–
- Pulmonary embolism	6 (18.8)	n/a	–
History of pulmonary embolism	8 (25.0)^a	4 (16.7)^b	0.525
Family history of DVT	10 (31.3)	3 (12.5)	0.122
Antithrombotic therapy	32 (100.0)	17 (70.8)	0.001
Antithrombotic therapy, type			0.071
- VKA	26 (81.3%)	16 (66.7)	0.212
- DOAC^c	6 (18.8%)	0 (0.0)	0.035
Elastic compression stockings, use	19 (59.4)	3 (12.5)	< 0.001

Data are n (%) or median (IQR)
DOAC Direct oral anticoagulant, DVT Deep venous thrombosis, LMWH Low Molecular Weight Heparin, n/a Not applicable, VKA Vitamin K Antagonist, VTE Venous Thrombo-Embolism
^a All pulmonary embolisms were recurrent VTE which developed after the primary thrombo-embolic event. In 6 patients it presented as a solitary pulmonary embolism and in 2 patients it presented concurrent with a recurrent deep-vein thrombosis
^b All pulmonary embolism were concurrent with the primary thrombo-embolic event
^c The DOACs used were Rivaroxaban (n = 4), Apixaban (n = 1), and Dabigatran (n = 1)

ISSN: 1477-9560